ASX 200
Checkout Our Recommendations for free - 7 day free trial Subscribe Now

Mayne Pharma Group Ltd - MYX share price

Current Price: $ - -
Updated At: -

About

Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.

Company Profile

Market Cap: -
Enterprise Value: -
Shares Outstanding: -
Shares Float: -
P/E Ratio: -
PEG Ratio: -
Book Value: -
Revenue TTM: -
Div Yield: -
Earning Share: -
Dividend per Share: -
Profit Margin: -

Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.

Top Shareholders

Price Summary

Today's High -
Price High
Today's Low -
Price Low
52 Week High: -
Price High
52 Week Low: -
Price Low
Price High
Week's High: -
Price Low
Week's Low: -

Price Chart

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...

Grab Your FREE Report on Top 5 ASX Stocks to Buy in 2026